Document is current
Any future updates will be listed below
-
Authors
Manski-Nankervis, Jo-Anne http://orcid.org/0000-0003-2153-3482
Thuraisingam, Sharmala
Sluggett, Janet K.
Kilov, Gary
Furler, John
O’Neal, David
Jenkins, Alicia
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim (N/A)
Eli Lilly and Company (N/A)
- License Information
-
More Information
Article History
Received: 9 August 2018
Accepted: 29 January 2019
First Online: 18 February 2019
Ethics approval and consent to participate
: Ethics approval for this study was provided by the University of Melbourne Health Sciences Ethics Committee (ID: 1749993) and data access was approved by MedicineInsight Data Governance Committee (APP 2017–013).
: Not applicable.
: JMN has had various financial relationships with pharmaceutical industries (MSD, Sanofi, Medtronic, Abbott) outside the submitted work including consultancies, grants, lectures, educational activities and travel. JF has received unrestricted educational grants for research support from Roche, Sanofi and Medtronic. JS has no conflict of interest to declare. AJ has received peer reviewed research grants from Medtronic, Sanofi-Aventis, Mylan, Firefly, Glen-Sys and has been on advisory boards for Abbott and Sanofi-Aventis. GK reports personal fees from Sanofi Diabetes, Novo Nordisk, Astra Zeneca, MSD and Boehringer-Ingelheim. DNO has received research and travel support and honorariums from Sanofi, Roche and Novo and is an advisory board member to Sanofi, Novo, and Abbott.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
